Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCardia Inc BCDA

Healthcare Biotechnology
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and... see more

Recent & Breaking News (NDAQ:BCDA)

BioCardia Announces Commercial Availability of Morph® DNA(TM) Steerable Introducer Product Family

GlobeNewswire 9 days ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

GlobeNewswire December 4, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

GlobeNewswire November 13, 2024

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

GlobeNewswire November 6, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

GlobeNewswire October 28, 2024

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

GlobeNewswire September 18, 2024

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire September 9, 2024

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire August 30, 2024

BioCardia Announces FDA Market Clearance of Morph® DNA(TM) Steerable Introducer Product Family

GlobeNewswire August 29, 2024

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

GlobeNewswire August 21, 2024

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

GlobeNewswire August 13, 2024

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

GlobeNewswire August 7, 2024

BioCardia Submits for FDA Approval of Morph® DNA(TM) Steerable Introducer Product Family

GlobeNewswire July 30, 2024

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

GlobeNewswire July 25, 2024

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

GlobeNewswire July 17, 2024

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes(TM) for the Treatment of Acute Myocardial Infarction

GlobeNewswire July 8, 2024

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

GlobeNewswire June 7, 2024

BioCardia Announces Reverse Stock Split

GlobeNewswire May 21, 2024

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

GlobeNewswire May 14, 2024

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

GlobeNewswire May 9, 2024